Unassociated Document Company Contact: Investor Relations Contact : Senesco Technologies, Inc. Lippert/Heilshorn & Associates, Inc. Jack Van Hulst Anne Marie Fields Chief Executive Officer ( afields@lhai.com ) ( jvanhuls

NAMES BIOPHARMACEUTICAL EXECUTIVE DR.

BROWNE AS PRESIDENT AND CEO

NEW BRUNSWICK, N.J. (May 24, 2010) -

Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT)

today announced that Leslie J. Browne, Ph.D., an accomplished executive in

biopharmaceutical drug development and clinical research, has been named

President and Chief Executive Officer of the Company, effective May 25,

2010. Dr. Browne, age 60, succeeds Jack van Hulst, who has served as

Senesco's CEO since November 2009 and remains a Director of the

Browne has more than 30 years of experience in the pharmaceutical industry

across multiple disciplines including R&D, operations and business

development. Most recently he was President and CEO of Phrixus

Pharmaceuticals, where he raised venture funding for the company's Phase II

clinical trial in heart failure. Previously he was President, CEO and

a Director of Pharmacopeia (now part of Ligand Pharmaceuticals), where he helped

transform the company into a clinical stage biopharmaceutical company with

multiple development programs, and raised more than $120 million from corporate

collaborations and institutional investors.

Browne also held key positions at Berlex/Schering AG, including Corporate Vice

President, Berlex Laboratories, and President of Schering Berlin Venture

Corporation. Earlier he was with Ciba-Geigy (now part of Novartis), where he

contributed to the discovery of Fadrozole , and was closely involved in the

discoveries of Femara and Diovan , which became major products for

Novartis. Dr. Browne recently served as a Director of Genelabs

Technologies, which was sold to GlaxoSmithKline, and was Chairman of the New

Jersey Technology Council.

Waksal, M.D., Chairman of the Board of Senesco, will introduce Dr. Browne at the

Company's Annual Meeting of Shareholders being held on Tuesday May 25, 2010 in

New York City. Commenting on the appointment, Dr. Waksal stated, "We

welcome Dr. Browne to the Senesco team, and are confident his vast professional

experience will be a strong asset as we build a leading biopharmaceutical

company. His skills will be valuable as we translate the expertise

we've developed with our proprietary gene-regulating platform technology to

develop and commercialize a pipeline of drug candidates to address unmet medical

needs in oncology and inflammatory diseases."

Waksal added, "We are especially grateful to Jack van Hulst for the excellent

job he has done during this transition period. Under his leadership

we have streamlined the Company, focused its clinical strategy on human

healthcare and, importantly, retired the Company's primary debt and raised $11

million in funding to advance its business plan. We thank him for his

service and commitment, and look forward to his continued contribution as a

valued member of our Board."

has an exciting and unique gene-regulating platform technology," commented Dr.

Browne. "I look forward to working with the Senesco team to maximize

the value of their work to date on SNS-01 in multiple myeloma, and to pursue a

variety of additional medical applications. My immediate focus will

be to advance this promising lead candidate into human clinical development and

to expand the awareness of Senesco's powerful platform technology."

Browne's academic background includes a National Institutes of Health

postdoctoral fellowship at Harvard University under the direction of Nobel

laureate Prof. R. B. Woodward, a Ph.D. in Organic Chemistry from the University

of Michigan, Ann Arbor, and a Bachelor of Science with Honors from Strathclyde

University, Glasgow, Scotland. He is named on 13 U.S. patents and has

authored more than 20 scientific articles.

Senesco Technologies, Inc.

Technologies is leveraging proprietary technology that regulates cell death, or

apoptosis. Accelerating apoptosis may have application in treating

cancer, while delaying apoptosis may have application in certain inflammatory

and ischemic diseases. The Company is preparing to initiative a human

clinical trial in multiple myeloma with its lead therapeutic

SNS-01. Senesco also has partnered with leading-edge companies

engaged in agricultural biotechnology, and earns research and development fees

for applying its gene-regulating platform technology to enhance its partners'

statements included in this press release are forward-looking statements within

the meaning of the Private Securities Litigation Reform Act of

1995. Actual results could differ materially from such statements

expressed or implied herein as a result of a variety of factors, including, but

not limited to: the ability of the Company to consummate additional financings;

the development of the Company's gene technology; the approval of the Company's

patent applications; the successful implementation of the Company's research and

development programs and joint ventures; the success of the Company's license

agreements; the acceptance by the market of the Company's products; success of

the Company's preliminary studies and preclinical research; competition and the

timing of projects and trends in future operating performance, the Company's

ability to meet its funding milestones under its financing transaction, the

Company's ability to continue to comply with the continued listing standards of

the AMEX, as well as other factors expressed from time to time in the Company's

periodic filings with the Securities and Exchange Commission (the

"SEC"). As a result, this press release should be read in conjunction

with the Company's periodic filings with the SEC. The forward-looking

statements contained herein are made only as of the date of this press release,

and the Company undertakes no obligation to publicly update such forward-looking

statements to reflect subsequent events or circumstances.